Literature DB >> 17949415

Tachykinin regulation of cholinergic transmission in the limbic/prefrontal territory of the rat dorsal striatum: implication of new neurokinine 1-sensitive receptor binding site and interaction with enkephalin/mu opioid receptor transmission.

Sylvie Pérez1, Adrienne Tierney, Jean-Michel Deniau, Marie-Louise Kemel.   

Abstract

The tachykinin neurokinin 1 receptors (NK(1)Rs) regulation of acetylcholine release and its interaction with the enkephalin/mu opioid receptors (MORs) transmission was investigated in the limbic/prefrontal (PF) territory of the dorsal striatum. Using double immunohistochemistry, we first showed that in this territory, cholinergic interneurons contain tachykinin NK(1)Rs and co-express MORs in the last part of the light period (afternoon). In slices of the striatal limbic/PF territory, following suppression of the dopaminergic inhibitory control of acetylcholine release, application of the tachykinin NK(1)R antagonist, SSR240600, markedly reduced the NMDA-induced acetylcholine release in the morning but not in the afternoon when the enkephalin/MOR regulation is operational. In the afternoon, the NK(1)R antagonist response required the suppression of the enkephalin/MOR inhibitory control of acetylcholine release by betafunaltrexamine. The pharmacological profile of the tachykinin NK(1)R regulation tested by application of the receptor agonists [[Pro(9)]substance P, neurokinin A, neuropeptide K, and substance P(6-11)] and antagonists (SSR240600, GR205171, GR82334, and RP67580) indicated that the subtype of tachykinin NK(1)R implicated are the new NK(1)-sensitive receptor binding site. Therefore, in the limbic/PF territory of the dorsal striatum, endogenous tachykinin facilitates acetylcholine release via a tachykinin NK(1)R subtype. In the afternoon, the tachykinin/NK(1)R and the enkephalin/MOR transmissions interact to control cholinergic transmission.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949415     DOI: 10.1111/j.1471-4159.2007.04944.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

2.  GABAergic inputs from direct and indirect striatal projection neurons onto cholinergic interneurons in the primate putamen.

Authors:  Kalynda Kari Gonzales; Jean-Francois Pare; Thomas Wichmann; Yoland Smith
Journal:  J Comp Neurol       Date:  2013-08-01       Impact factor: 3.215

Review 3.  Roles of micro-opioid receptors in GABAergic synaptic transmission in the striosome and matrix compartments of the striatum.

Authors:  Masami Miura; Masao Masuda; Toshihiko Aosaki
Journal:  Mol Neurobiol       Date:  2008-05-13       Impact factor: 5.590

4.  Control of striatal signaling by g protein regulators.

Authors:  Keqiang Xie; Kirill A Martemyanov
Journal:  Front Neuroanat       Date:  2011-08-08       Impact factor: 3.856

Review 5.  Cholinergic modulation of striatal microcircuits.

Authors:  Nilupaer Abudukeyoumu; Teresa Hernandez-Flores; Marianela Garcia-Munoz; Gordon W Arbuthnott
Journal:  Eur J Neurosci       Date:  2018-11-29       Impact factor: 3.386

6.  Substance P Weights Striatal Dopamine Transmission Differently within the Striosome-Matrix Axis.

Authors:  Katherine R Brimblecombe; Stephanie J Cragg
Journal:  J Neurosci       Date:  2015-06-17       Impact factor: 6.167

7.  Metabolic control of daily locomotor activity mediated by tachykinin in Drosophila.

Authors:  Sang Hyuk Lee; Eunjoo Cho; Sung-Eun Yoon; Youngjoon Kim; Eun Young Kim
Journal:  Commun Biol       Date:  2021-06-07

8.  The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.

Authors:  Frances E Lennon; Tamara Mirzapoiazova; Bolot Mambetsariev; Valeriy A Poroyko; Ravi Salgia; Jonathan Moss; Patrick A Singleton
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.